The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: PharmaGap

Monday Deal Review: May 13, 2013

Welcome to your Monday Biotech Deal Review for May 13, 2013! This week saw MethylGene make waves with its announcement that it will move its business to the State of Delaware, and will be held by specially made Mirati Therepeutics.  Mirati will then seek listing on the NASDAQ. It is unclear how long the company will be trading on both the TSX and the NASDAQ together. In other news, iCo has priced an overnight marketing of units for proceeds of about $3.2 million, while Sirona has rasied another $1 milllion, beinging their 2013 total to a healthy $2.4 million.  Click on through to get the rest of the past week’s major biotech news!     Read more of this post

Monday Deal Review: October 15, 2012

Welcome to your Monday Biotech Deal Review for October 15, 2012.  Thanks to Thanksgiving for the Canadians and Columbus day for the Americans out there, this week’s post covers the last two weeks of activity.  Biggest of the weeks’ stories, however, is Aeterna Zentaris Inc.’s $15 million public offering, closing in mid October.  Read onwards to see just how busy this fall the market is shaping up to be. 
Read more of this post

Monday Deal Review: August 27, 2012

Welcome to your Monday Biotech Deal Review for August 27, 2012.  Highlights from the previous two weeks include Miraculins Inc’s grant of stock options and distribution agreement with London Drugs, Microbix Biosyetem’s licensing of a thrombolytic biopharmaceutical to Zydus Cadila, and BIOREM’s closing of its private placement.  The Monday Deal Review for August 13, 2012 also marked the last Review authored by Jacob Cawker.  We’d like to thank Jacob for his hard work and years of service! For more about me, please see my Bio, here.  Read on to learn more. Read more of this post

Monday Biotech Deal Review: August 13, 2012

Welcome to your Monday Biotech Deal Review for August 13, 2012.  Highlights from the previous two weeks include the announcement of an interim order for a plan of arrangement between QHR Technologies Inc. and Open EC Technologies and the announcement of a support agreement for the takeover of Life Bank by Insception Biosciences.  Read on to learn more. Read more of this post

Monday Biotech Deal Review: July 9, 2012

Welcome to your Monday Biotech Deal Review for July 9, 2012.  Highlights from the previous two weeks include the announcement of a $13.25 million prospectus offering by Trimel Pharmaceuticals, and the announcement of a $200 million exchange offer by Angiotech on its Senior Floating Rate Notes due 2013.  Read on to learn more. Read more of this post

Monday Biotech Deal Review: January 23, 2012

Welcome to your Monday Biotech Deal Review for January 23, 2012.  Noteworthy news from the previous week include the sweetening of the offer by Valeant for ISTA Pharmaceuticals by an additional dollar per share ($7.50 from $6.50), and the adoption by ISTA of a shareholder rights plan to replace its recently expired plan.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: January 16, 2012

Welcome to your Monday Biotech Deal Review for January 16, 2012.   News from last week includes a  $5M raise by MedGenesis Therapeutics to support its therapeutic research for the treatment of Parkinson’s Disease, as well as a $70k private placement by PharmaGap.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: December 12, 2011

Welcome to your Monday Biotech Deal Review for December 12, 2011.  Microbix and PharmaGap each completed private placements, together raising over $1 million.  As well, Nuvo Research is purchasing the minority interest in its German subsidiary from Dr. Friedrich-Wilherm Kuehne.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: December 5, 2011

Welcome to your Monday Biotech Deal Review for December 5, 2011.  Some equity investment activity occurred over the previous week, with Resverlogix closing its previously announced $17.5M private placement, Response Biomedical announcing an $8M rights offering, and various other small private placements.  As well, Valeant is going to fund its acquisition of iNova with debt, as summarized further below.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: November 14, 2011

Welcome to your Monday Biotech Deal Review for November 14, 2011, marking the end of its one month hiatus.  The Monday Biotech Deal Review will now be resuming its normal weekly schedule.  Below are summaries of recent transactions over the past month, which includes the acquisition of Afexa by Valeant for $0.85 per Afexa share, in cash.    Read on to learn more.  Read more of this post

Monday Biotech Deal Review: September 26, 2011

Welcome to your Monday Biotech Deal Review for September 26, 2011.  Noteworthy news from last week included a hint that Labopharm will enhance its offer for the shares of Afexa Life Sciences if its two shareholder rights plans are waived or cease-traded by the ASC.  As well, Medicago announced a significant private placement for proceeds of up to $24.5M, and Valeant has announced its intention to refinance its secured credit facilities with a new $1.7bn facility.  Read more of this post

Monday Biotech Deal Review: August 22, 2011

Welcome to your Monday Biotech Deal Review for August 22, 2011.  This week’s deal review is brought to you by Norton Rose OR LLP articling student Keldeagh Lindsay, who will be with us during his articles and assisting in the deal review.  Steven Zuccarelli has done a great job over the summer, and we wish him well in his final year at law school.  

There has been quite a lot of activity over the previous two weeks, with significant equity investment activity, debt financings (public and private), and mergers and acquisitions on the go.  Read on to learn more. Read more of this post

Monday Biotech Deal Review: August 8, 2011

Welcome to your Monday Biotech Deal Review for August 8, 2011.  The previous two weeks witnessed a flurry of investment activity, including the filing of final prospectuses by each of Lorus Therapeutics and Atrium Innovations in respect of equity and debt offerings, respectively.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review

Welcome to your Monday Biotech Deal Review for July 18, 2011.  Of note over the past week was the completion of Trimel’s qualifying transaction under the TSX-V’s capital pool company regime, resulting in Trimel’s expected re-listing on the TSX.  Also noteworthy was Valeant’s buying spree in the dermatology sector, with the purchase of dermatology assets from both Janssen Pharmaceuticals and Sanofi.  Read on to learn more. Read more of this post

Monday Biotech Deal Review: May 16, 2011

Welcome to your Monday Biotech Deal Review for May 16, 2011. Angiotech has completed its second amended and restated plan of compromise or arrangement, cleaning up USD$250M in debt in respect of 7.75% senior subordinated notes, which are now cancelled, and has also resulted in the restructuring of $325M of existing floating rate notes through an exchange transaction.  There was also interesting licensing activity, notably involving Paladin Labs.  Lastly, Arch Biopartners announced their development achievement of a “bio-steel” material that is approximately 40% harder and 50% less corrosive than regular stainless steel.  Read on to learn more.   Read more of this post

Monday Biotech Deal Review: March 21, 2011

Welcome to your Monday Biotech Deal Review for March 21, 2011.  There was some interesting investment and commercial transactions announced and closed last week, including the $15M private placement announced by Novadaq, the $4M bond financing closed by SemBioSys and Pacgen’s announcement of a corporate makeover to accommodate its recent investments in the products of General Biologicals Corporation.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: February 28, 2011

Welcome to your Monday biotech deal review for February 28, 2011.  In addition to the usual reviews of biotech corporate activity, this week featured the announcement of Theratechnologies’ U.S. IPO, the closing of a $40M bought deal by Paladin Labs, Angiotech’s recapitalization amendment and the appointment of a Receiver for LAB Research.  Read on to learn more.   Read more of this post

Monday Biotech Deal Review: February 14, 2011

Welcome to the Monday Biotech Deal Review for February 14, 2011.  Aside from the usual assortment of corporate and regulatory announcements over the week, the highlights include SemBioSys’ proposed $4M secured 7% bond issuance, Angiotech’s fifth extension to deadlines under its recapitalization support agreements (and definitive agreements in respect of up to $28M in DIP financing), Med Biogene is being accused of breaching confidentiality and exclusivity agreements and former biotech Bradmer Pharmaceuticals is migrating to the oil and gas industry via a proposed reverse takeover.  Read on to learn more.   Read more of this post

Monday Biotech Deal Review: November 22, 2010

Welcome to your Monday Deal Review.  There was quite a bit of Canada / U.S. crossborder investment activity last week, with a $700M note offering by Valeant, IMRIS’ USD$52M public offering, and both IMRIS and Tekmira announcing their listing on the NASDAQ.   Read on to learn more, as well as the usual summaries of recent biotech activity. Read more of this post

Monday Deal Review: November 8, 2010

Welcome to your Monday Deal Review.  The Canadian biotech sector was fairly busy this week, with approximately $17M in investment money flowing into biotech companies reviewed below.  Valeant is certainly raking the leaves this fall following the Biovail merger, settling lawsuits, entering a $1.5bn securities repurchase program, and entering strategic agreements this week after ending a collaboration last week.  Read on to learn more, as well as the usual assortment of biotech news.  Read more of this post

Monday Deal Review: July 20, 2009

B&W_BigNickelThis week’s deal review has some more info about Ambrilia’s deal with Kotinos that I tweeted about at the time (my Twitter stream shows up in the sidebar on the right here), as well as an update on JLL-Patheon and a raft of securities deals, including an issuer bid after the jump…

Monday Deal Review: June 29, 2009

B&W_BigNickelThis week’s Monday Deal Review has a full set of equity deals from shelf to launch to close, one new U.S. registration and one deregistration to match, and some ideas for what to do with your debt (!), all after the jump…

Monday Deal Review: June 22, 2009

B&W_BigNickelA whole gaggle of securities deals, a cluster of licenses and a flock of M&A all migrate back to Canada for summer in this week’s Monday Deal Review.  Plus, a deal that may improve the medical isotope shortage.   after the jump…

Monday Deal Review: March 30, 2009

Monday Deal Review: March 23, 2009

A relativley light week for Canadian deal and company info this week, but we have all the news that’s fit to print (if not necessarily fit to distribute in the U.S.) after the jump…

Monday Deal Review: March 2, 2009

Monday Deal Review: February 23, 2009

Monday Deal Review: February 16, 2009

An interesting collection of goings-on in this week’s special President’s Day / Family Day edition of the Monday Deal Review after the jump…

Follow

Get every new post delivered to your Inbox.

Join 126 other followers